Replimune (REPL) Plunges 30% After FDA Briefing Raises Concerns on RP1 Melanoma Therapy

The Quick Take

• REPL shares plunged 30% after the FDA briefing raised material concerns about the RP1 melanoma therapy.
• FDA briefing concerns at this stage typically signal a higher likelihood of rejection or additional study requirements.
• The selloff wipes out significant market cap and raises questions about Replimune's clinical development path.

Replimune's shares collapsed 30% after the U.S. Food and Drug Administration issued a pre-advisory committee briefing that raised material concerns about the company's RP1 melanoma therapy. FDA briefing documents typically surface the agency's primary objections ahead of advisory committee meetings, and when they contain significant safety or efficacy concerns, markets interpret them as leading indicators of potential rejection or requests for additional clinical data.

RP1 (vusolimogene oderparepvec) is an oncolytic virus therapy being evaluated for advanced melanoma treatment. The therapy works by selectively replicating in tumor cells, triggering immune system activation against the cancer. Clinical trial results had shown meaningful response rates in certain patient populations, which is why the FDA's briefing concerns represent a significant setback — the delta between investor expectations and regulatory reality is the primary driver of the 30% selloff.

For investors in oncology biotech, this outcome underscores the critical importance of FDA briefing document analysis as a pre-event signal. Briefings that raise concerns — particularly around safety signals, comparator arm design, or patient population selection — substantially increase the probability of a negative advisory committee vote or Complete Response Letter. Replimune must now decide whether to proceed to the advisory committee, submit additional analyses, or withdraw the application pending a revised dataset.

Synthesized from 1 source — full coverage, sentiment breakdown, and forward signals below.